Medindia

X

Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology

Friday, June 18, 2010 Research News J E 4
Advertisement
New Data from Five Clinical Studies Reinforce RDEA594's Robust Efficacy and Encouraging Safety Profile

PK/PD Study Interim Results

sUA Response - % of Patients

Treatment Groups

Allopurinol 300 mg

Alone

(n = 11)

RDEA594 400 mg

+ Allopurinol 300 mg

(n = 6)

RDEA594 600 mg

+ Allopurinol 300 mg

(n = 5)

< 6 mg/dL

27%

100%

100%

< 5 mg/dL

9%

67%

100%

< 4 mg/dL

0%

0%

60%

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Mylan Receives Approval for Generic Version of Zoc...
S
Sinovac Schedules 2010 Annual Meeting of Sharehold...